Full Professor
Strategic program(s):
Biography
Prof Dr Monique Minnema was trained as internist and hematologist at Academic Medical Center, Amsterdam and the University Medical Center, Utrecht. She started working as a hematologist in 2005 at the department of hematology, UMC Utrecht and was appointed full professor in 2019. She is specialized in the diagnosis and treatment of B cell malignancies, especially plasma cell dyscrasis like Multiple Myeloma, AL amyloidosis, and Waldenstrom Macroglobulinemia. Prof Minnema is author on several national and internatonial quidelines on the diagnosis and treatment of these diseases.
She is head supervisor of the hematology clinical research team, the hematology biobank and the European expertise reference network (ERN) malignant hematology of the UMC Utrecht. Her main focus of clinical research is the development of novel therapies (both cellular and drug) for plasma cell dyscrasias and the development of new research structures for hematology research in the Netherlands.
Prof Dr Minnema is vice chairperson of the HOVON working partie for Multiple
Myeloma, and member of the Lymphoma and IEC working parties. Examples of her work are the HOVON 104 trial and the use of the monoclonal antibody Daratumumab for patients with AL amyloidosis in first line treatment, the clinical studies with Daratumumab and the bispecific antibody Talquetamab in relapsed Multiple Myeloma the use of anti CD19 CAR T cells in relapsed Lymphoma. Her translational research focuses on 3D models to predict response to therapy and the use of combined immunotherapy for relapsed multiple myeloma.
She was a member of the organizing committee of the Waldenström workshop in Amsterdam in 2016, and is co initiator of the yearly Immune Effector Cell Symposium and the current chair of the Systemic Amyloidosis symposium in the Netherlands
Research aim
Our research aim is to control cellular life and death decisions to improve treatment of B cell cancers and allow T cell immunotherapy for untreatable cancers.Research aim
To develop, validate and implement decision support systems based on imaging for the diagnosis, prognosis and triaging of oncology patients2017: Dutch Cancer Society/KWF Research Project: Personalized strategy to avert drug resistance in hematologic cancers.
Data Monitoring Committee for Galapagos’ ongoing hematological clinical trial programs - voorzitter - Galapagos
Myeloom Werkgroep - Vice voorzitter - HOVON
Commissie Dataregistratie en Cohorten - voorzitter - HOVON
voorzitter - Myeloom Werkgroep commissie CART - HOVON
Commissie Wetenschap en Onderzoek - voorzitter - NVvH
European Consortium for Waldenstrom’s Macroglobulinemia - lid - ECWM
International Myeloma Working Group - lid - IMWG
EXCALIBER Data Monitoring Committee - lid - BMS
Aquarius Steering Committee - lid - Janssen
Scientific Advisory Sub-Committee on the WM Global Awareness Building Initiative - lid - IWMF
Medical Advisory Committee - lid - MPE
Beoordelingscommissie Ontwikkeling en Implementatie - lid - KWF
Algemeen bestuur - lid - NVvH
Lymfoom Werkgroep - Lid - HOVON
Immune Effector Cell werkgroep - Lid - HOVON
